Phase II study of cyclophosphamide, etoposide and estramustine in patients with androgen independent prostate cancer

4708 Background: Novel and effective therapies for patients with AIPC are needed. Oral therapy offers the tremendous advantage of independence and avoids all the catheter-related complications. Cyclophosphamide, etoposide and estramustine have shown synergistic activity against AIPC. The optimal dose and schedule of these agents have not been defined. Our goal is to develop an effective and easy to administer oral palliative regimen that does not require hospitalization or intravenous access. Methods: Objectives are to evaluate the efficacy and safety of this triple drug regimen. Each treatment cycle consists of cyclophosphamide 50 mg/m2 p.o., etoposide 50 mg/m2 p.o. and estramustine 280 mg p.o. administered on days 1–14, every 28 days. Response was assessed by RECIST guidelines (JNCI 92(3):205–216, 2000), and PSA levels (PSA Working Group JCO 17(11):3461–7, 1999). Results: From October, 2001 to December, 2003, 15 subjects with AIPC were enrolled. All patients are evaluable for toxicity and 14, who comple...